- $1.45bn
- $1.39bn
- $1.11bn
- 87
- 57
- 63
- 79
Annual income statement for Omnicell, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 892 | 1,132 | 1,296 | 1,147 | 1,112 |
| Cost of Revenue | |||||
| Gross Profit | 416 | 555 | 597 | 500 | 476 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 857 | 1,043 | 1,298 | 1,182 | 1,112 |
| Operating Profit | 35.5 | 89.5 | -2.32 | -34.9 | 0.337 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 29.3 | 66 | -2.45 | -20.1 | 25.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 32.2 | 77.8 | 5.65 | -20.4 | 12.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 32.2 | 77.8 | 5.65 | -20.4 | 12.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 32.2 | 77.8 | 5.65 | -20.4 | 12.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.884 | 1.8 | 0.446 | -0.227 | 0.325 |